Keytruda: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
Lauren Riley (talk | contribs) No edit summary |
||
| Line 6: | Line 6: | ||
== Mechanism == | == Mechanism == | ||
[http://www.nature.com/articles/srep35297/figures/2 A schematic diagram of polar interactions] | |||
===Pembrolizumab/PD-1 Interaction=== | ===Pembrolizumab/PD-1 Interaction=== | ||
In order for Pembrolizumab to block PD-1, Pembrolizumab forms a large, flat paratope (antigen-binding site) that can sustain PD-1’s large epitope (where antibody attaches on antigen). The induced interaction between Pembrolizumab and PD-1 gives rise to a surface conformational change on PD-1. The new structure of PD-1 becomes a very shallow, “crescent”-like shape, in contrast to the flat conformation when bound to PD-L1 <ref name="horita">DOI:10.1038/srep35297</ref>. | In order for Pembrolizumab to block PD-1, Pembrolizumab forms a large, flat paratope (antigen-binding site) that can sustain PD-1’s large epitope (where antibody attaches on antigen). The induced interaction between Pembrolizumab and PD-1 gives rise to a surface conformational change on PD-1. The new structure of PD-1 becomes a very shallow, “crescent”-like shape, in contrast to the flat conformation when bound to PD-L1 <ref name="horita">DOI:10.1038/srep35297</ref>. | ||
